NCT02975921

Brief Summary

The purpose of this study is to determine whether betadine (povidone-iodine) instillation during routine indwelling Tunneled Pleural Catheter (TPC) placement is efficacious in promoting pleurodesis and thus reducing the time to TPC removal.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2018

Typical duration for phase_4

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 17, 2016

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 29, 2016

Completed
1.6 years until next milestone

Study Start

First participant enrolled

July 1, 2018

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

January 11, 2019

Status Verified

January 1, 2019

Enrollment Period

2.2 years

First QC Date

November 17, 2016

Last Update Submit

January 9, 2019

Conditions

Keywords

Pleural EffusionThoracentesisPleural CavityPleurodesisTunneled Pleural Catheter

Outcome Measures

Primary Outcomes (1)

  • Time to Tunneled Pleural Catheter Removal

    The time (in days) between Tunneled Pleural Catheter (TPC) placement to eventual removal within 6 months

    0-6 months

Secondary Outcomes (18)

  • Pleurodesis Rate

    2 months

  • Infection Rate

    6 months

  • Death

    6 months

  • Mechanical Complications

    6 months

  • Baseline Borg Dyspnea Index

    Baseline

  • +13 more secondary outcomes

Study Arms (4)

Malignant Effusion - Usual Care

NO INTERVENTION

Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.

Malignant Effusion with Pleurodesis

EXPERIMENTAL

Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.

Drug: Povidone-Iodine

Benign Effusion - Usual Care

NO INTERVENTION

Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.

Benign Effusion with Pleurodesis

EXPERIMENTAL

Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.

Drug: Povidone-Iodine

Interventions

Intrapleural administration of Povidone-Iodine

Also known as: Betadine
Benign Effusion with PleurodesisMalignant Effusion with Pleurodesis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Requiring Tunneled Catheter Placement for a Pleural Effusion

You may not qualify if:

  • Patient with a nonexpandable lung
  • Non-english speaker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Agarwal R, Khan A, Aggarwal AN, Gupta D. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012 Mar;135(3):297-304.

    PMID: 22561614BACKGROUND
  • Ahmed L, Ip H, Rao D, Patel N, Noorzad F. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. Chest. 2014 Dec;146(6):e190-e194. doi: 10.1378/chest.14-0394.

    PMID: 25451360BACKGROUND
  • Hak CC, Sivakumar P, Ahmed L. Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation. BMC Pulm Med. 2016 Mar 11;16:41. doi: 10.1186/s12890-016-0203-7.

    PMID: 26968653BACKGROUND
  • Light RW. Pleural effusions. Med Clin North Am. 2011 Nov;95(6):1055-70. doi: 10.1016/j.mcna.2011.08.005. Epub 2011 Sep 25.

    PMID: 22032427BACKGROUND
  • Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest. 2014 Oct;146(4):991-1000. doi: 10.1378/chest.13-2481.

    PMID: 24832000BACKGROUND
  • Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011 Jan;26(1):70-6. doi: 10.1007/s11606-010-1472-0. Epub 2010 Aug 10.

    PMID: 20697963BACKGROUND
  • Walker S, Bibby AC, Maskell NA. Current best practice in the evaluation and management of malignant pleural effusions. Ther Adv Respir Dis. 2017 Feb;11(2):105-114. doi: 10.1177/1753465816671697. Epub 2016 Oct 24.

    PMID: 27777372BACKGROUND

MeSH Terms

Conditions

Pleural EffusionPleural Effusion, MalignantBronchiolitis Obliterans Syndrome

Interventions

Povidone-Iodine

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract DiseasesPleural NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsOrganizing PneumoniaBronchiolitis ObliteransBronchiolitisBronchitisBronchial DiseasesLung Diseases, ObstructiveLung DiseasesGraft vs Host DiseaseImmune System Diseases

Intervention Hierarchy (Ancestors)

IodophorsIodine CompoundsInorganic ChemicalsPolyvinylsVinyl CompoundsAlkenesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsPovidonePyrrolidinonesPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPlasticsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and Agriculture

Study Officials

  • Jonathan T Puchalski, MD, MEd

    Yale University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 17, 2016

First Posted

November 29, 2016

Study Start

July 1, 2018

Primary Completion

September 1, 2020

Study Completion

June 1, 2021

Last Updated

January 11, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share